Cargando…

Clinical ACO phenotypes: Description of a heterogeneous entity

BACKGROUND: Because ACO (Asthma-COPD-Overlap) does not fill out asthma or COPD (Chronic Obstructive Pulmonary Disease) criteria, such patients are poorly evaluated. The aim of this study was to screen asthma and COPD for an alternative diagnosis of ACO, then to determine subgroups of patients, using...

Descripción completa

Detalles Bibliográficos
Autores principales: Lainez, S., Court-Fortune, I., Vercherin, P., Falchero, L., Didi, T., Beynel, P., Piperno, D., Frappe, E., Froudarakis, M., Vergnon, J.M., Devouassoux, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733899/
https://www.ncbi.nlm.nih.gov/pubmed/31516821
http://dx.doi.org/10.1016/j.rmcr.2019.100929
_version_ 1783450049962835968
author Lainez, S.
Court-Fortune, I.
Vercherin, P.
Falchero, L.
Didi, T.
Beynel, P.
Piperno, D.
Frappe, E.
Froudarakis, M.
Vergnon, J.M.
Devouassoux, G.
author_facet Lainez, S.
Court-Fortune, I.
Vercherin, P.
Falchero, L.
Didi, T.
Beynel, P.
Piperno, D.
Frappe, E.
Froudarakis, M.
Vergnon, J.M.
Devouassoux, G.
author_sort Lainez, S.
collection PubMed
description BACKGROUND: Because ACO (Asthma-COPD-Overlap) does not fill out asthma or COPD (Chronic Obstructive Pulmonary Disease) criteria, such patients are poorly evaluated. The aim of this study was to screen asthma and COPD for an alternative diagnosis of ACO, then to determine subgroups of patients, using cluster analysis. MATERIAL AND METHODS: Using GINA-GOLD stepwise approach, asthmatics and COPD were screened for ACO. Clusterization was then performed employing Multiple Correspondent Analysis (MCA) model, encompassing 9 variables (age, symptoms onset, sex, BMI (Body Mass Index), smoking, FEV-1, dyspnea, exacerbation, comorbidity). Finally, clusters were compared to determine phenotypes. RESULTS: MCA analysis was performed on 172 ACO subjects. To better distinguish clusters, the analysis was then focused on 55 subjects, having at least one cosine squared >0.3. Six clusters were identified, allowing the description of 4 phenotypes. Phenotype A represented overweighed heavy smokers, with an early onset and a severe disease (27% of ACO patients). Phenotype B gathered similar patients, with a late onset (29%). Patients from Phenotypes C-D were slighter smokers, presenting a moderate disease, with early and late onset respectively (respectively 13% and 31%). CONCLUSIONS: By providing evidences for clusters within ACO, our study confirms its heterogeneity, allowing the identification of 4 phenotypes. Further prospective studies are mandatory to confirm these data, to determine both specific management requirements and prognostic value.
format Online
Article
Text
id pubmed-6733899
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67338992019-09-12 Clinical ACO phenotypes: Description of a heterogeneous entity Lainez, S. Court-Fortune, I. Vercherin, P. Falchero, L. Didi, T. Beynel, P. Piperno, D. Frappe, E. Froudarakis, M. Vergnon, J.M. Devouassoux, G. Respir Med Case Rep Case Report BACKGROUND: Because ACO (Asthma-COPD-Overlap) does not fill out asthma or COPD (Chronic Obstructive Pulmonary Disease) criteria, such patients are poorly evaluated. The aim of this study was to screen asthma and COPD for an alternative diagnosis of ACO, then to determine subgroups of patients, using cluster analysis. MATERIAL AND METHODS: Using GINA-GOLD stepwise approach, asthmatics and COPD were screened for ACO. Clusterization was then performed employing Multiple Correspondent Analysis (MCA) model, encompassing 9 variables (age, symptoms onset, sex, BMI (Body Mass Index), smoking, FEV-1, dyspnea, exacerbation, comorbidity). Finally, clusters were compared to determine phenotypes. RESULTS: MCA analysis was performed on 172 ACO subjects. To better distinguish clusters, the analysis was then focused on 55 subjects, having at least one cosine squared >0.3. Six clusters were identified, allowing the description of 4 phenotypes. Phenotype A represented overweighed heavy smokers, with an early onset and a severe disease (27% of ACO patients). Phenotype B gathered similar patients, with a late onset (29%). Patients from Phenotypes C-D were slighter smokers, presenting a moderate disease, with early and late onset respectively (respectively 13% and 31%). CONCLUSIONS: By providing evidences for clusters within ACO, our study confirms its heterogeneity, allowing the identification of 4 phenotypes. Further prospective studies are mandatory to confirm these data, to determine both specific management requirements and prognostic value. Elsevier 2019-08-27 /pmc/articles/PMC6733899/ /pubmed/31516821 http://dx.doi.org/10.1016/j.rmcr.2019.100929 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Lainez, S.
Court-Fortune, I.
Vercherin, P.
Falchero, L.
Didi, T.
Beynel, P.
Piperno, D.
Frappe, E.
Froudarakis, M.
Vergnon, J.M.
Devouassoux, G.
Clinical ACO phenotypes: Description of a heterogeneous entity
title Clinical ACO phenotypes: Description of a heterogeneous entity
title_full Clinical ACO phenotypes: Description of a heterogeneous entity
title_fullStr Clinical ACO phenotypes: Description of a heterogeneous entity
title_full_unstemmed Clinical ACO phenotypes: Description of a heterogeneous entity
title_short Clinical ACO phenotypes: Description of a heterogeneous entity
title_sort clinical aco phenotypes: description of a heterogeneous entity
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733899/
https://www.ncbi.nlm.nih.gov/pubmed/31516821
http://dx.doi.org/10.1016/j.rmcr.2019.100929
work_keys_str_mv AT lainezs clinicalacophenotypesdescriptionofaheterogeneousentity
AT courtfortunei clinicalacophenotypesdescriptionofaheterogeneousentity
AT vercherinp clinicalacophenotypesdescriptionofaheterogeneousentity
AT falcherol clinicalacophenotypesdescriptionofaheterogeneousentity
AT didit clinicalacophenotypesdescriptionofaheterogeneousentity
AT beynelp clinicalacophenotypesdescriptionofaheterogeneousentity
AT pipernod clinicalacophenotypesdescriptionofaheterogeneousentity
AT frappee clinicalacophenotypesdescriptionofaheterogeneousentity
AT froudarakism clinicalacophenotypesdescriptionofaheterogeneousentity
AT vergnonjm clinicalacophenotypesdescriptionofaheterogeneousentity
AT devouassouxg clinicalacophenotypesdescriptionofaheterogeneousentity